Fundz

Moderna

Cambridge, Massachusetts, United States · Biopharma, Biotechnology, Health Care

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one o

Key facts

Headquarters
Cambridge, Massachusetts, United States
Employees
5,800
Industries
Biopharma, Biotechnology, Health Care
Status
Public (MRNA)
Website
modernatx.com
LinkedIn
Company page

Recent activity at Moderna

  • : Moderna Appoints Juan Andres as Chief Operating Officer
  • : Moderna Appoints Ester Banque as Chief Commercial Officer
  • : Moderna Reports Strong Revenue Due to Partnership with UK Government (date Fundz recorded it)
  • : Moderna Enters Settlement Agreement to Resolve Patent Litigation (date Fundz recorded it)
  • : SEC 8-K (1.01):
  • : SEC 8-K (5.02): On September 30, 2026, Moderna, Inc. announced the appointment of Juan Andres as its new Chief Operating Officer (COO), effective October 5, 2026. This newly created position is intended to support the company's increasing scale and diversification. Mr. Andres has a notable history with Moderna, having previously served as the Chief Technical Operations and Quality Officer from 2018 to 2022 and President of Strategic Partnerships and Enterprise Expansion before retiring in 2023. His extensive experience is expected to enhance the company's operational strategies moving forward.
  • : SEC 8-K (1.01): On September 1, 2026, Moderna, Inc. completed a private offering of $3,000,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2032. This includes the exercise of an additional $400,000,000 option by initial purchasers. The indenture for these notes was also executed on the same date, specifying that interest will not be regular but special interest may accrue under certain conditions. Holders can convert the notes under specific circumstances as detailed in the indenture, impacting the company’s capital structure and financial flexibility significantly.
  • : SEC 8-K (5.02): On July 6, 2026, Moderna, Inc. appointed Michael McDonnell to its Board of Directors, effective July 8, 2026. McDonnell brings over 35 years of experience in financial leadership, having previously served as CFO of Biogen Inc. from August 2020 to February 2025, and also held CFO positions at IQVIA Holdings Inc., Intelsat S.A., MCG Capital Corporation, and EchoStar Communications. He will serve as a Class II director until the 2029 annual meeting of shareholders and will also join the Audit Committee, while David Rubenstein transitions to the Nominating and Corporate Governance Committee. This change is part of the routine board refreshment and governance strategy within the company.
  • : SEC 8-K (1.01): On March 3, 2026, Moderna, Inc. and ModernaTX, Inc. (collectively 'Moderna') entered into a Settlement Agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH to resolve all patent infringement litigation related to their vaccine products. The agreement entails a $950 million noncontingent payment to be made by Moderna by July 8, 2026, resolving litigation over products such as Spikevax® and mRESVIA®. Furthermore, there is a contingent payment of up to $1.3 billion based on the outcome of appeals and court decisions related to claims of patent infringement. This settlement aims to secure Moderna's vaccine pipeline and remove future royalty obligations, providing significant strategic clarity moving forward.
  • : SEC 8-K (1.01): On March 3, 2026, Moderna, Inc. entered into a Settlement Agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH to resolve all patent infringement litigation relating to its Spikevax and mRESVIA products. This agreement eliminates the need for future royalty payments and solidifies Moderna's portfolio for infectious diseases, paving the way for its mNEXSPIKE and mCOMBRIAX products as well as its vaccine pipeline. Additionally, Moderna will make a one-time payment of $950 million to Arbutus/Genevant as part of the settlement. This strategic move aims to secure and enhance Moderna's operational capabilities in the competitive vaccine market.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Moderna funding history

DateRoundAmount
Mar 2024Funding Round$750.0M
Aug 2016Venture$451.4M

Leadership

  • Henri Termeer, Director
  • Elizabeth Nabel, Director
  • John Mendlein, Director
  • Robert Langer, Director
  • Peter Hutt, Director
  • Lee Babiss, Director
  • Noubar Afeyan, Director
  • Stephane Bancel, Executive Officer, Director
  • Patrick Bergstedt, Senior Vice President / General Manager – Asia and Emerging Markets
  • Juan Andres, Chief Operating Officer
  • Ester Banque, Chief Commercial Officer
  • David Berman, Chief Development Officer

Verified email and direct lines for Moderna’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Moderna files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Moderna in the news

Companies similar to Moderna

About Moderna: questions and answers

What does Moderna do?

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one o

Where is Moderna headquartered?

Moderna is headquartered in Cambridge, Massachusetts, United States.

How many employees does Moderna have?

Moderna has about 5,800 employees.

Has Moderna raised funding?

Yes. Fundz has recorded 2 funding events for Moderna. The most recent, Funding Round of $750.0M, was in Mar 2024.

Who leads Moderna?

Patrick Bergstedt is a Senior Vice President / General Manager – Asia and Emerging Markets at Moderna.

What is the latest news on Moderna?

On Sep 30, 2026, Moderna Appoints Juan Andres as Chief Operating Officer

Is Moderna a public company?

Yes. Moderna is publicly traded under the ticker MRNA.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Moderna across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.